Analysts Set Expectations for RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the biotechnology company will post earnings per share of ($3.20) for the year. Cantor Fitzgerald has a “Overweight” rating and a $65.00 price objective on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

RCKT has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Scotiabank initiated coverage on Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Jefferies Financial Group assumed coverage on Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $29.00 target price on the stock. Wedbush assumed coverage on shares of Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an “outperform” rating and a $32.00 price target for the company. Finally, Leerink Partners decreased their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $47.27.

Rocket Pharmaceuticals Trading Up 3.1 %

Shares of RCKT stock opened at $10.48 on Thursday. The business has a 50-day simple moving average of $12.46 and a 200-day simple moving average of $16.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals has a 52-week low of $10.07 and a 52-week high of $31.47.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.07.

Institutional Trading of Rocket Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of Rocket Pharmaceuticals by 22.8% in the third quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company’s stock valued at $207,642,000 after purchasing an additional 2,086,424 shares during the period. State Street Corp raised its position in Rocket Pharmaceuticals by 11.6% during the 3rd quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company’s stock worth $57,294,000 after buying an additional 322,156 shares during the last quarter. Maverick Capital Ltd. lifted its stake in shares of Rocket Pharmaceuticals by 4.8% in the 3rd quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company’s stock worth $76,072,000 after acquiring an additional 190,360 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Rocket Pharmaceuticals by 3.8% in the third quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock valued at $83,001,000 after acquiring an additional 165,911 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Rocket Pharmaceuticals during the third quarter worth about $2,556,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Insider Activity

In related news, CEO Gaurav Shah sold 11,091 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total value of $144,737.55. Following the completion of the transaction, the chief executive officer now owns 707,328 shares in the company, valued at approximately $9,230,630.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 13,490 shares of company stock worth $176,045 over the last ninety days. Corporate insiders own 28.50% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.